--News Direct--
AccuStem Sciences Inc CEO Wendy Blosser joined Steve Darling from Proactive to share more details about the company that started as a spinout of Tiziana Life Sciences to focus on three primary healthcare verticals including pharmaceuticals, diagnostics or devices.
The company’s main product is StemPrintER which is a 20-gene test using stem cells to predict cancer recurrence.
Blosser telling Proactive more about the technology and where they see the biggest opportunities. One of those is a recent announcement that saw the company agree to a joint clinical collaboration agreement with University Hospitals.
She says that agreement will provide tissue samples with clinical outcomes to AccuStem for research purposes. The agreement covers different cancers but will initially focus on breast cancer.
Contact Details
Proactive Investors
+1 604-688-8158
na-editorial@proactiveinvestors.com
View source version on newsdirect.com: https://newsdirect.com/news/accustem-sciences-agrees-to-joint-collaboration-with-university-hospitals-727373760
